Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

fasiglifam

- PMLiVE

Novo Nordisk fends off Lilly’s GLP-1 challenge in Q1

Insulin specialist bounces back with encouraging signs from Ozempic launch

- PMLiVE

Shire warms to Takeda’s latest offer, extending deadline

The new offer is £5 per share higher than Takeda’s opening bid

Shire Basingstoke

Morning brief: Takeda closes in on $64bn merger, GSK unveils team, and more

A rapid run-down of news in pharma, biotech and healthcare

- PMLiVE

Will Shire agree to extend Takeda takeover talks?

UK rules mean Shire must agree to extend deadline

- PMLiVE

Shire rebuffs Takeda bids, as Allergan bows out

Allergan doesn’t intend to make a formal offer following a dip in its share prices

- PMLiVE

Takeda mulls bid for Irish biopharma Shire

The Japanese pharma firm must make a formal offer by 25 April

- PMLiVE

Takeda’s Alofisel becomes Europe’s first allogeneic stem cell therapy

Will treat perianal fistulas in adult patients with Crohn’s disease

Takeda explores the potential of ‘digital biomarkers’

Collaborates with Mindstrong Health on mental health research

- PMLiVE

Novo’s oral semaglutide ‘safe and well-tolerated’

Releases first phase III data on the new version of its diabetes treatment

dengue fever mosquito

Takeda gets FDA fast-track status for Zika vaccine

The phase I candidate also has the backing of US federal funding body BARDA

- PMLiVE

Takeda and Zinfandel abandon Alzheimer’s drug

Pioglitazone failed to show therapeutic improvements in late-stage testing

- PMLiVE

Takeda bags EU approval for Adcetris in lymphoma

Data shows the drug improves PFS and symptom burden in CTCL patients

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links